Advanced Micro Devices Inc/ US0079031078 /
5/17/2024 3:30:55 PM | Chg. +1.66 | Volume | Bid5:30:00 PM | Ask5:30:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
154.84EUR | +1.08% | 244 Turnover: 36,769.14 |
-Bid Size: - | -Ask Size: - | 244.63 bill.EUR | - | - |
Newsfile Corp
5/16
FDA Grants AI-Powered Notal Vision Home OCT "SCANLY" De Novo Marketing Authorization
GlobeNewswire
5/15
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Cor...
GlobeNewswire
5/14
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facilit...
GlobeNewswire
5/14
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/13
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire
5/13
AMD Remains the Partner of Choice for World’s Fastest and Most Efficient High Performance Computing ...
GlobeNewswire
5/9
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/9
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlight...
GlobeNewswire
5/8
Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progress...
GlobeNewswire
5/8
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire
5/8
AMD Receives IEEE 2024 Corporate Innovation Award for Leadership in Chiplet Design for High-Performa...
GlobeNewswire
5/8
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
GlobeNewswire
5/8
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporat...
GlobeNewswire
5/7
Optiver Chooses AMD Enterprise Portfolio to Power its Data Center Modernization, Enabling New Era of...
GlobeNewswire
5/6
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
GlobeNewswire
5/6
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ...
GlobeNewswire
5/6
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...